Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1. Free Radic Biol Med. 2019. PMID: 30391585 Free article.
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14. Free Radic Biol Med. 2019. PMID: 30880247 Free article.
Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M, Pérez-Barrios C, Barquin M, Calvo V, Franco F, Sánchez E, Sánchez R, Marsden D, Cristóbal Sánchez J, Martin Acosta P, Laza-Briviesca R, Cruz-Bermúdez A, Romero A. Provencio M, et al. Clin Chem Lab Med. 2020 Jan 28;58(2):306-313. doi: 10.1515/cclm-2019-0745. Clin Chem Lab Med. 2020. PMID: 31469650
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Sierra-Rodero B, et al. Among authors: laza briviesca r. J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. J Immunother Cancer. 2021. PMID: 34446577 Free PMC article.
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A, Serna-Blasco R, Alfaro C, Sánchez-Herrero E, Barquín M, Turpin MC, Chico S, Sanz-Moreno S, Rodrigez-Festa A, Laza-Briviesca R, Cruz-Bermudez A, Calvo V, Royuela A, Provencio M. Romero A, et al. Among authors: laza briviesca r. Transl Lung Cancer Res. 2020 Jun;9(3):532-540. doi: 10.21037/tlcr.2020.04.01. Transl Lung Cancer Res. 2020. PMID: 32676317 Free PMC article.
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Laza-Briviesca R, et al. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Clin Transl Med. 2021. PMID: 34323406 Free PMC article.
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Casarrubios M, et al. Among authors: laza briviesca r. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376534 Free PMC article.
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R, Sánchez-Herrero E, Sanz-Moreno S, Rodriguez-Festa A, García-Veros E, Casarrubios M, Sierra-Rodero B, Laza-Briviesca R, Cruz-Bermúdez A, Mielgo-Rubio X, Sánchez-Hernández A, Uribelarrea EA, Calvo V, Romero A, Provencio M. Serna-Blasco R, et al. Among authors: laza briviesca r. ESMO Open. 2021 Oct;6(5):100279. doi: 10.1016/j.esmoop.2021.100279. Epub 2021 Oct 1. ESMO Open. 2021. PMID: 34607284 Free PMC article.
23 results